Comparable stake leader
GILEAD SCIENCES, INC.
SEC ownership of Arcellx, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001786205.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- ACLX on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GILEAD SCIENCES, INC.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GILEAD SCIENCES, INC.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001786205
- Issuer location
- Redwood City, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Arcellx, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GILEAD SCIENCES, INC.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 100%
13D/G row: GILEAD SCIENCES, INC.
Showing 1-8 of 50 holder rows.
Quick read
GILEAD SCIENCES, INC. leads the comparable SEC ownership view at 100%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GILEAD SCIENCES, INC.'s linked filing trail.
Comparable ownership
Top 5
GILEAD SCIENCES, INC.
100%
Paradigm Biocapital Advisors LP
9.9%
BlackRock, Inc.
6.4%
T. Rowe Price Investment Manageme...
4.5%
PERCEPTIVE ADVISORS LLC
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
100%
from 13D/G
|
$771,682,600
6,720,803 shares
|
— | 31 Mar 2026 |
| Paradigm Biocapital Advisors LP |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$662,972,517
5,774,016 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.4%
from 13D/G
|
$452,992,229
3,945,238 shares
|
— | 31 Mar 2026 |
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
Company
|
4.5%
from 13D/G
|
$259,020,000
2,255,878 shares
|
— | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC |
13D/G
|
4.5%
|
$162,432,900
2,478,000 shares
|
-$29,397,733 | 30 Jun 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
2.2%
|
$83,974,428
1,267,156 shares
|
$0 | 31 Dec 2025 |
| FMR LLC |
13D/G
13F
Company
|
0.5%
|
$21,601,128
309,117 shares
|
-$227,432,217 | 27 Feb 2026 |
| NEA Management Company, LLC |
13F
Company
|
3045262%
|
$349,656,983
3,045,262 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$18,641,783.
Buys
$0
Insiders: 0
Sells
$18,641,783
Insiders: 4
Net
-$18,641,783
Shares: -195,056
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 195,056
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 146,260 | $0 | $14,611,067 | -$14,611,067 |
| 6-9 | 0 | 45,153 | $0 | $3,739,248 | -$3,739,248 |
| 9-12 | 0 | 3,643 | $0 | $291,468 | -$291,468 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to Arcellx, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
GILEAD SCIENCES, INC.
Net 12M change
-$18,641,783
Latest report
28 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10%+ Owner | $371,444,668 | Mixed | 28 Dec 2023 | ||
| NEA Partners 15, L.P. | 10%+ Owner | $262,260,666 | Mixed | 20 Dec 2022 | ||
| New Enterprise Associates 15, L.P. | 10%+ Owner | $262,260,666 | Mixed | 20 Dec 2022 | ||
| Novo Holdings A/S | 10%+ Owner | $222,004,412 | Mixed | 08 Feb 2022 | ||
| Lewis T. "rusty" Williams | Director | $115,792,551 | Mixed | 08 Feb 2022 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | $91,677,287 | Mixed | 11 May 2023 | ||
| Michelle Gilson | Chief Financial Officer | $9,500,159 | -$3,634,223 | -28% | Mixed | 28 Apr 2026 |
| Mohamad Makhzoumi | 10%+ Owner | $15,641 | Mixed | 20 Dec 2022 | ||
| Peter W. Sonsini | 10%+ Owner | $663 | Mixed | 20 Dec 2022 | ||
| Rami Elghandour | President, CEO and Chairman of the Board, Director | $0 | -$10,243,267 | -100% | Mixed | 28 Apr 2026 |
| Ali Behbahani | Director | $0 | Mixed | 28 Apr 2026 | ||
| Andrew H. Galligan | Director | $0 | Mixed | 28 Apr 2026 | ||
| David Charles Lubner | Director | $0 | -$450,000 | -100% | Mixed | 28 Apr 2026 |
| Jill Carroll | Director | $0 | Mixed | 28 Apr 2026 | ||
| Christopher Heery | Chief Medical Officer | $0 | -$4,314,293 | -100% | Mixed | 28 Apr 2026 |
| Kavita Patel | Director | $0 | Mixed | 28 Apr 2026 | ||
| Forest Baskett | 10%+ Owner | Mixed | 20 Dec 2022 | |||
| Scott D. Sandell | 10%+ Owner | Mixed | 23 Dec 2022 | |||
| Lance E. Thibault | Interim Chief Financial Officer Exhibit 24 - Power of Attorney | Mixed | 03 Feb 2022 | |||
| Olivia C. Ware | Director | Mixed | 28 Apr 2026 |
Recent insider transactions for Arcellx, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jill Carroll | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -1,479,148 | 0 | 28 Apr 2026 | See Note 2 | ||
| Jill Carroll | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -28,644 | 0 | 28 Apr 2026 | Direct | ||
| Ali Behbahani | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -2,706 | 0 | 28 Apr 2026 | See Note 2 | ||
| Ali Behbahani | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -1,925 | 0 | 28 Apr 2026 | Direct | ||
| Ali Behbahani | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -28,644 | 0 | 28 Apr 2026 | Direct | ||
| Olivia C. Ware | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -65,450 | 0 | 28 Apr 2026 | Direct | ||
| Kavita Patel | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -76,234 | 0 | 28 Apr 2026 | Direct | ||
| Kristin Myers | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -18,613 | 0 | 28 Apr 2026 | Direct | ||
| David Charles Lubner | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -21,659 | 0 | 28 Apr 2026 | Direct | ||
| David Charles Lubner | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -195,007 | 0 | 28 Apr 2026 | Direct | ||
| Andrew H. Galligan | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -5,000 | 0 | 28 Apr 2026 | By trust | ||
| Andrew H. Galligan | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -18,613 | 0 | 28 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -5,000 | 0 | 28 Apr 2026 | By foundation | ||
| Michelle Gilson | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -67,048 | 0 | 28 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Performance-based Restricted Stock Unit | Disposed to Issuer | -100% | -59,028 | 0 | 28 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Performance-based Restricted Stock Unit | Award | 59,028 | 59,028 | 28 Apr 2026 | Direct | |||
| Michelle Gilson | ACLX | Restricted Stock Unit | Disposed to Issuer | -100% | -170,628 | 0 | 28 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -238,097 | 0 | 28 Apr 2026 | Direct | ||
| Christopher Heery | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -23,749 | 0 | 28 Apr 2026 | Direct | ||
| Christopher Heery | ACLX | Performance-based Restricted Stock Unit | Disposed to Issuer | -100% | -45,138 | 0 | 28 Apr 2026 | Direct | ||
| Christopher Heery | ACLX | Performance-based Restricted Stock Unit | Award | 45,138 | 45,138 | 28 Apr 2026 | Direct | |||
| Christopher Heery | ACLX | Restricted Stock Unit | Disposed to Issuer | -100% | -119,923 | 0 | 28 Apr 2026 | Direct | ||
| Christopher Heery | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -363,259 | 0 | 28 Apr 2026 | Direct | ||
| Rami Elghandour | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -101,164 | 0 | 28 Apr 2026 | By foundation | ||
| Rami Elghandour | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -416,500 | 0 | 28 Apr 2026 | By trust | ||
| Rami Elghandour | ACLX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -174,887 | 0 | 28 Apr 2026 | Direct | ||
| Rami Elghandour | ACLX | Performance-based Restricted Stock Unit | Disposed to Issuer | -100% | -571,021 | 0 | 28 Apr 2026 | Direct | ||
| Rami Elghandour | ACLX | Performance-based Restricted Stock Unit | Award | 571,021 | 284,388 | 28 Apr 2026 | Direct | |||
| Rami Elghandour | ACLX | Restricted Stock Unit | Disposed to Issuer | -100% | -431,765 | 0 | 28 Apr 2026 | Direct | ||
| Rami Elghandour | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -810,102 | 0 | 28 Apr 2026 | By trust | ||
| Rami Elghandour | ACLX | Stock Option (right to buy) | Disposed to Issuer | -100% | -2,526,637 | 0 | 28 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Common Stock | Options Exercise | 3.25% | 2,110 | 67,048 | 16 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Stock Option (right to buy) | Options Exercise | -4.99% | -2,110 | 40,205 | 16 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Common Stock | Options Exercise | 124.4% | 36,000 | 64,938 | 15 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Stock Option (right to buy) | Options Exercise | -46% | -36,000 | 42,315 | 15 Apr 2026 | Direct | ||
| Michelle Gilson | ACLX | Common Stock | Gift | -14.7% | -5,000 | 28,938 | 17 Mar 2026 | Direct | ||
| Rami Elghandour | ACLX | Common Stock | Gift | -36.6% | -101,164 | 174,887 | 04 Mar 2026 | Direct | ||
| Rami Elghandour | ACLX | Common Stock | Sale | -24.6% | $10,243,267 | $113.92 | -89,916 | 276,051 | 27 Feb 2026 | Direct |
| Michelle Gilson | ACLX | Common Stock | Sale | -24.8% | $1,276,954 | $113.82 | -11,219 | 33,938 | 25 Feb 2026 | Direct |
| Michelle Gilson | ACLX | Common Stock | Sale | -15.7% | $572,568 | $68.29 | -8,384 | 45,157 | 19 Feb 2026 | Direct |
| Michelle Gilson | ACLX | Common Stock | Sale | -17.4% | $784,783 | $69.51 | -11,291 | 53,541 | 17 Feb 2026 | Direct |
| Rami Elghandour | ACLX | Common Stock | Gift | -35.1% | -198,000 | 365,967 | 11 Feb 2026 | Direct | ||
| Rami Elghandour | ACLX | Common Stock | Gift | -27.9% | -218,500 | 563,967 | 11 Feb 2026 | Direct | ||
| David Charles Lubner | ACLX | Common Stock | Sale | -21.7% | $450,000 | $75.00 | -6,000 | 21,659 | 20 Jan 2026 | Direct |
| David Charles Lubner | ACLX | Common Stock | Options Exercise | 27.7% | 6,000 | 27,659 | 20 Jan 2026 | Direct | ||
| David Charles Lubner | ACLX | Stock Option (right to buy) | Options Exercise | -9.17% | -6,000 | 59,405 | 20 Jan 2026 | Direct | ||
| Christopher Heery | ACLX | Common Stock | Sale | -19.8% | $402,997 | $68.51 | -5,882 | 23,749 | 14 Jan 2026 | Direct |
| Christopher Heery | ACLX | Common Stock | Sale | -20.1% | $487,213 | $65.51 | -7,437 | 29,631 | 13 Jan 2026 | Direct |
| Christopher Heery | ACLX | Common Stock | Sale | -14.2% | $393,286 | $64.15 | -6,131 | 37,068 | 12 Jan 2026 | Direct |
| Rami Elghandour | ACLX | Common Stock | Options Exercise | 7.71% | 55,991 | 782,467 | 06 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.